Clinical trial

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

NCT07820111

Study summary

ClinicalTrials.gov

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Dulaglutide 1.5 MG/ML Normalized identity: dulaglutide 1.5 MG/ML View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Dulaglutide 0.75mg subcutaneous injection Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Semaglutide 1.0 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tirzepatide (Flexible titration) Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2025-10-18

PhasePHASE3

Conditions

Obese Diabeticsunresolved

Obese Non Diabeticunresolved

Interventions

Dulaglutide 1.5 MG/MLDRUG · verified · RxNorm: dulaglutide 1.5 MG/ML

Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solutionDRUG

Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physicianDRUG

Dulaglutide 0.75mg subcutaneous injectionDRUG

Semaglutide 1.0 mgDRUG

Tirzepatide (Flexible titration)DRUG

Sponsors & collaborators

Zagazig Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07820111 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.